Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease

NCT05308160 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05308160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05308160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
Lead sponsor
National Taiwan University Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 28, 2021
Completion date
April 30, 2024
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fatty liver